145 related articles for article (PubMed ID: 10870876)
1. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
Yoshimura R; Nakamura J; Ueda N; Terao T
Int Clin Psychopharmacol; 2000 May; 15(3):175-80. PubMed ID: 10870876
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
4. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
Yoshimura R; Hori H; Sugita A; Ueda N; Kakihara S; Umene W; Nakano Y; Shinkai K; Mitoma M; Ohta M; Shinkai T; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1072-7. PubMed ID: 17459549
[TBL] [Abstract][Full Text] [Related]
5. Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment.
Kaneko M; Honda K; Kanno T; Horikoshi R; Manome T; Watanabe A; Kumashiro H
Neuropsychobiology; 1992; 25(3):126-9. PubMed ID: 1357582
[TBL] [Abstract][Full Text] [Related]
6. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
[TBL] [Abstract][Full Text] [Related]
7. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.
Zhou ZL; Li X; Peng HY; Yu XY; Yang M; Su FL; Wang F; Zhu RH; Deng CY; Lin QX; Wang CY; Li WB; Lin SG; Li HD
Acta Pharmacol Sin; 2006 Mar; 27(3):381-6. PubMed ID: 16490177
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
9. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Ancione M; Madia AG; Perucca E
Psychopharmacology (Berl); 2001 Jan; 153(2):238-43. PubMed ID: 11205425
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Vermeulen A; Piotrovsky V; Ludwig EA
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
[TBL] [Abstract][Full Text] [Related]
11. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.
Yoshimura R; Ueda N; Nakamura J
Neuropsychobiology; 2001; 44(3):129-33. PubMed ID: 11586052
[TBL] [Abstract][Full Text] [Related]
12. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.
Nagasaki T; Ohkubo T; Sugawara K; Yasui N; Furukori H; Kaneko S
J Pharm Biomed Anal; 1999 Mar; 19(3-4):595-601. PubMed ID: 10704125
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Yoshimura R; Shinkai K; Ueda N; Nakamura J
Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.
Lee DY; Lee KU; Kwon JS; Jang IJ; Cho MJ; Shin SG; Woo JI
Psychopharmacology (Berl); 1999 Jun; 144(3):272-8. PubMed ID: 10435394
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
18. Plasma risperidone concentrations during combined treatment with sertraline.
Spina E; D'Arrigo C; Migliardi G; Morgante L; Zoccali R; Ancione M; Madia A
Ther Drug Monit; 2004 Aug; 26(4):386-90. PubMed ID: 15257068
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
Saito M; Yasui-Furukori N; Nakagami T; Furukori H; Kaneko S
J Clin Psychopharmacol; 2005 Dec; 25(6):527-32. PubMed ID: 16282832
[TBL] [Abstract][Full Text] [Related]
20. Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.
Chen PS; Yang YK; Su SF; Liao YC; Chang JW; Yeh TL
Psychiatry Clin Neurosci; 2004 Apr; 58(2):168-72. PubMed ID: 15009822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
